Advertisement

Neurology pp 477-486 | Cite as

Autoradiographic Distributions of Neurotransmitter Receptors in the Brain of Patients with Parkinson’s Disease and MPTP-induced Monkey Parkinsonism

  • S. Kito
  • R. Miyoshi
  • K. Mizuno
  • K. Nitta
  • H. Matsubayashi
  • Y. Yamamura
Conference paper

Abstract

Parkinson’s disease is a slowly progressive degenerative disorder which is pathologically characterized by neuronal loss of the substantia nigra. Biochemically, deficiency of dopamine in the striatum resulting from degeneration and loss of dopaminergic neurons in the substantia nigra has been confirmed. In addition, from experiments using autopsied human materials [1–6], abnormalities have been reported in the dopaminergic as well as in the following systems: acetylcholine, GABA, serotonin, noradrenaline, and peptide-containing neurons. Recently, it was discovered that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a by-product in the synthesis of MPPP (1-methyl-4-phenyl-4-propionoxy-piperidine), is selectively toxic to the zona compacta of the substantia nigra [7]. In this paper, we report on observed distributions of neurotransmitter receptors in brains of patients with Parkinson’s disease and those of primate models with MPTP-induced parkinsonism.

Keywords

Substantia Nigra Globus Pallidus Ergot Alkaloid Neurotransmitter Receptor Zona Compacta 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) [3H] spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175PubMedCrossRefGoogle Scholar
  2. 2.
    Llorens-Cortes C, Javoy-Agid F, Agid Y, Taquet H, Schwartz JC (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from parkinsonian subjects. J Neurochem 43: 874–877PubMedCrossRefGoogle Scholar
  3. 3.
    Lloyd KD, Shemen L, Hornykiewicz O (1977) Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid ([3H]GABA) binding in the human brain: alterations in Parkinson’s disease. Brain Res 127: 269–278CrossRefGoogle Scholar
  4. 4.
    Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 34: 642–646PubMedGoogle Scholar
  5. 5.
    Reisine TD, Fields JZ, Yamamura HI, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344PubMedCrossRefGoogle Scholar
  6. 6.
    Tenovuo O, Rinne UK, Viljanen MK (1984) Substance P immunoreactivity in the postmortem parkinsonian brain. Brain Res 303: 113–116PubMedCrossRefGoogle Scholar
  7. 7.
    Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars com- pacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550PubMedCrossRefGoogle Scholar
  8. 8.
    Youg III W, Kuhar MJ (1979) A new method for receptor autoradiography: [3H] opioid receptors in rat brain. Brain Res 179: 255–279CrossRefGoogle Scholar
  9. 9.
    Fuxe K, Agnati LF, Kohler C, Andersson K, Eneroth P, Calza L, Ogren SO (1983) Heterogeneity of brain dopamine systems: possible discrimination of different types of dopamine systems and receptors by ergot drugs. In: Calne DB (ed) Lisuride and other dopamine agonists. Raven, New York, pp 11–31Google Scholar
  10. 10.
    Spano PF, Govoni S, Uzumaki H, Bosio A, Memo M, Lucchi L, Carruba M, Trabucchi M (1983) Stimulation of D2 dopamine receptors by dopaminergic ergot alkaloids: studies on the mechanism of action. In: Agonoli A (ed) Aging brain and ergot alkaloids. Raven, New York, pp 165–177Google Scholar
  11. 11.
    Rosenfeld MR, Makman MH (1981) The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol and Exp Ther 216: 526–531Google Scholar
  12. 12.
    Cote TE, Eskay RL, Frey EA, Crewe CW, Munemura M, Tsuruta K, Brouwn EM, Kebabian JW (1983) Actions of lisuride on adrenoceptors and dopamine receptors. In: Calne DB (ed) Lisuride and other dopamine agonists. Raven, New York, pp 45–53Google Scholar
  13. 13.
    Hong JS, Yang HYT, Racagni G, Costa E (1977) Projections of substance P containing neurons from neostriatum to substantia nigra. Brain Res 122: 541–544PubMedCrossRefGoogle Scholar
  14. 14.
    Kanazawa I, Emson PC, Cuello AC (1977) Evidence for the existence of substance P containing fibers in striato-nigral and pallido-nigral pathways in rat brain. Brain Res 119: 447–453PubMedCrossRefGoogle Scholar
  15. 15.
    Morz EA, Brownstein MJ, Leeman SE (1977) Evidence for substance P in the striato-nigral tract. Brain Res 125: 305–311CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • S. Kito
  • R. Miyoshi
  • K. Mizuno
  • K. Nitta
  • H. Matsubayashi
  • Y. Yamamura
    • 1
  1. 1.Third Department of Internal MedicineHiroshima University School of MedicineMinami-ku, HiroshimaJapan

Personalised recommendations